Caitong International Asset Management’s Silence Therapeutics SLN Stock Holding History

Caitong International Asset Management’s Portfolio SLN Stock Details SLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$16	Buy	+3	New	+$17	﹤0.01%	2096

Other funds holding SLN

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Citadel Advisors

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Caitong International Asset Management's SLN Position: Q1 2026 in Review

Caitong International Asset Management opened a new position in Silence Therapeutics (SLN) in Q1 2026: 3 shares worth $16. The stake represents ﹤0.01% of the portfolio and ranks #2096 among its holdings.

56 funds tracked by Wall St. Rank hold SLN as of Q1 2026.

Caitong International Asset Management held 3 shares of Silence Therapeutics worth $16 as of Q1 2026.
Silence Therapeutics was a new Caitong International Asset Management position in Q1 2026.
Silence Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q1 2026, its #2096 holding.
56 funds tracked by Wall St. Rank held Silence Therapeutics as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.